These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 23972263)

  • 1. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
    Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
    Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
    PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
    Higashihara E; Nutahara K; Okegawa T; Tanbo M; Mori H; Miyazaki I; Nitatori T; Kobayashi K
    Clin Exp Nephrol; 2015 Aug; 19(4):746-52. PubMed ID: 25351823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
    Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
    Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
    J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.
    Ruggenenti P; Remuzzi A; Ondei P; Fasolini G; Antiga L; Ene-Iordache B; Remuzzi G; Epstein FH
    Kidney Int; 2005 Jul; 68(1):206-16. PubMed ID: 15954910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial.
    Trillini M; Caroli A; Perico N; Remuzzi A; Brambilla P; Villa G; Perna A; Peracchi T; Rubis N; Martinetti D; Caruso M; Leone VF; Cugini D; Carrara F; Remuzzi G; Ruggenenti P;
    Clin J Am Soc Nephrol; 2023 Feb; 18(2):223-233. PubMed ID: 36754009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic kidney disease: Trial of a long-acting somatostatin analogue for autosomal dominant polycystic kidney disease.
    Allison SJ
    Nat Rev Nephrol; 2013 Oct; 9(10):553. PubMed ID: 24018411
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.
    Spinelli L; Pisani A; Giugliano G; Trimarco B; Riccio E; Visciano B; Remuzzi G; Ruggenenti P;
    Int J Cardiol; 2019 Jan; 275():145-151. PubMed ID: 30509370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALADIN: wish granted in inherited polycystic kidney disease?
    Qian Q; Wang HY
    Lancet; 2013 Nov; 382(9903):1469-71. PubMed ID: 23972262
    [No Abstract]   [Full Text] [Related]  

  • 13. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
    JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
    Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
    J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
    Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
    Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.